GBM Clinical Trial
Official title:
A Multicenter, Randomized, Open-label, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
This is a multicenter, randomized, controlled study, aiming to evaluate the efficacy and safety of CAN008 administered once-weekly with rRT for treating first tumor recurrence in patients with GBM.
This is a multi-center, randomized, controlled clinical trial to evaluate the efficacy and
safety of CAN008 administered once-weekly with re-radiation therapy (rRT) in patients with an
initial relapse of GBM. The subjects will be randomized into the treatment group (CAN008 +
rRT) or the control group (rRT). The investigational treatment can be continued as long as
the subjects have experienced lasting clinical benefits (complete response [CR], partial
response [PR] or stable disease [SD]).
This study will be carried out in GBM subjects with an initial or second relapse. The
subjects must have received standard care, including combination of radiotherapy and TMZ
after surgical resection, and must be candidates for re-radiation therapy (rRT).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06147505 -
Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
| Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
| Completed |
NCT01478178 -
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03119064 -
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
| Recruiting |
NCT03758014 -
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients
|
Phase 2/Phase 3 | |
| Terminated |
NCT01205334 -
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00114309 -
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
|
Phase 2 | |
| Recruiting |
NCT04681677 -
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
|
Phase 2 | |
| Completed |
NCT01856933 -
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
|
Phase 2 | |
| Terminated |
NCT04763031 -
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT
|
N/A | |
| Completed |
NCT00107003 -
GW572016 to Treat Recurrent Malignant Brain Tumors
|
Phase 2 | |
| Completed |
NCT03426891 -
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT06092255 -
A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.
|
N/A | |
| Recruiting |
NCT04115761 -
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
|
Phase 2 | |
| Recruiting |
NCT05954858 -
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
|
N/A | |
| Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03341806 -
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
|
Phase 1 |